Biogen brags of Phase III data for would-be Aubagio rival oral MS drug

Share this article:
A study published in the New England Journal of Medicine indicates that Biogen Idec's experimental MS drug, BG-12 is on track to make an impression. The study said patients taking the oral medication had a significantly lower annual relapse rate at two years when taking the drug two or three times a day, compared with placebo. The study did not show the drug had any significant impact on slowing disease progression.

Thursday's news brings the drug one step closer to its built-in fan base. It also comes a week after the FDA approved Sanofi's oral contender, Aubagio (teriflunomide). Phase III trials of Sanofi's therapy reduced the relapse rate among MS patients by about 30%. Industry watchers told MM&M at the time that the approval expanded patient options, but it was going to have a longer acceptance curve among physicians than BG-12, which has cultivated a level of pre-approval confidence with its safety and efficacy profile.

Ben Weintraub, director of research at the health analytics firm InThought, told MM&M at the time of Sanofi's Augbagio approval that this will translate into doctor preference for the Biogen Idec drug over rivals like Aubagio or Tysabri for second-line use when interferon and Copaxone fail.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.